Prioritizing Mental Health in South African Medical Schemes: Challenges and Opportunities

By HEOR Staff Writer

May 1, 2023

Medical schemes in South Africa are prioritizing mental health as a key component of managed care services. In 2019 CMS published a PMB definition guidelines for mental health emergencies.

“It is still concerning that beneficiaries of medical schemes attracted copayments as high as five (5%) for services such as a psychiatry benefit. Prior studies have also found that medical scheme members affected by mental illness and in most cases were discriminated against by funders. There needs to be a concerted effort to reprioritise mental health,” said Willie

A study analysed data from 2014-2018 and found the most prevalent mental disorders in South Africa in 2017 were anxiety and depression. However, only schizophrenia and bipolar mood disorder are the only conditions included in the PMB Chronic Diseases List (CDLs).

It is worrying that mental disorders like depression and anxiety are not covered under PMBs. We need a review of PMBs to include these conditions. A designated medical scheme provider should consider resource scarcity and co-payment rules.

Reference url

Recent Posts

Transformative PBM Reform Legislation Signed into Law

By João L. Carapinha

February 16, 2026

PBM Reform Legislation Signed into Law President Trump signed a comprehensive spending bill incorporating landmark PBM reform legislation, ending a partial government shutdown while targeting pharmacy benefit managers (PBMs) with transformativ...
Advancing Cancer Screening in Slovenia: A Pathway to Equitable Care
Spotlight on Cancer Screening Slovenia at Strategic Conference Cancer screening Slovenia took center stage at Slovenia’s 6th Strategic Conference "Living with Cancer," held at the National Council of the Republic of Slo...
Late-Breaking Data on Bladder Cancer Treatments from KEYNOTE-B15 Trial

By HEOR Staff Writer

February 13, 2026

Breakthroughs in Bladder Cancer Treatments at ASCO GU Merck unveiled promising bladder cancer treatments at the 2026 ASCO Genitourinary (GU) Cancers Symposium, showcasing data from its portfolio including KEYTRUDA® (pembrolizuma...